knowledge -WSS

knowledge

author：hotspot 2025-09-29 23:27:04 - browse：5

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Why Charlie Gard's case is so disturbing to Americans

WSS

Phenylephrine and the overlooked value of the placebo effect

A new study asks: Are we harming blood donors by taking blood?

Senate panel eyes new effort on drug shortages

FDA panel signals lack of confidence in Amgen cancer drug data

Chan Zuckerberg Biohub Chicago to focus on inflammation

AI can decode, harness the power of the humane immune system

explore

knowledge

focus

Medical records are filled with copy

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bill would stop addiction treatment from triggering child abuse inquiry

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Connecting traumatic brain injury and domestic violence

Tori Bowie and the unacceptable rates of Black maternal death

A virus, fished out of a lake, may have saved a man’s life

Continuity nursing helped my family in our darkest PICU moments

Bacterial infection may be ‘key event’ in endometriosis, study says

explore

Senate panel eyes new effort on drug shortages

The future of health care in the House

VC firm General Catalyst wants to buy a health system

Chan Zuckerberg Biohub Chicago to focus on inflammation

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

PhRMA sues HHS over Medicare drug price negotiation

focus

hotspot

entertainment

explore